SOURCE: 3D Signatures inc.

December 05, 2016 12:16 ET

3D Signatures Adds Leading Commercial Diagnostics Lab Executive to Advisory Board

WINNIPEG, MB--(Marketwired - December 05, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce the appointment of Mr. Nigel Terrett to 3DS' Business Advisory Board ("BAB"). Mr. Terrett will provide the Company with strategic insight and guidance related to commercial lab partnerships and information technology management for its diagnostic platform. Mr. Terrett brings extensive commercial lab experience to 3DS which includes executive roles with several major commercial labs and electronic health record companies such as Excelleris Technologies, Lifelabs Inc. and MDS Diagnostics Inc.

Nigel Terrett

Nigel Terrett has held executive leadership roles at Excelleris Technologies, LifeLabs, MDS Inc. and MDS Diagnostics. His significant accomplishments in the life sciences sector include his tenure as Chairman of the Board of Excelleris Technologies, a medical information technology company, where he led the creation of the largest integrated patient and physician diagnostic database in Canada. As Chief Strategic Officer of LifeLabs Inc., Mr. Terrett created innovative collaborative programs with health institutions, provincial governments and health providers to improve health care while reducing costs. As Senior Vice President and General Manager of Life Labs British Columbia, Mr. Terrett was responsible for 900 operational staff, 90 branch locations and two state-of-the-art medical laboratories providing over 15 million medical results per year. In this role, he dramatically improved operational performance through Lean-Sigma methodologies. As Chief Information Officer of MDS Diagnostics Inc., he led the restructuring of information technology services that resulted in multi-million dollar savings for the company. As Vice-President of Information Technology at MDS Diagnostics, Mr. Terrett led a North American team that increased operating income by over 50%. More recently, Mr. Terrett has provided strategic advisory services to the biotech industry.

Mr. Terrett is experienced in every step of the diagnostics testing process, from sample collection to reporting, to providing efficient, reliable and high-quality services to enhance patient care. A respected industry leader, Mr. Terrett's operational background and network will help facilitate the successful launch of 3DS' new class of minimally invasive biomarker tests at a national level.

Comments from Chairman

"We are honored to welcome Nigel Terrett to the Business Advisory Board," commented John Swift, Chairman of 3D Signatures Inc. "His guidance in the development and commercialization of our entirely new class of minimally invasive biomarkers will be invaluable, given his extensive history of success in the medical diagnostics industry. Mr. Terrett will help us navigate the complex commercial laboratory marketplace, such that we ensure physicians and patients have access to 3D Signatures' product pipeline, that we believe to be at the forefront of specialized clinical tests in the cancer and Alzheimer's space."

About 3DS

3DS (TSX VENTURE: DXD) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's new website at http://www.3dsignatures.com.

Forward-Looking Information

This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. In particular, the Company's statements that it expects to benefit greatly from its association with the individuals named in this news release is forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company's existing products or the Company's ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company's financial condition; the Company's ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information